Alternative tumour-specific antigens
The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …
accelerated within the past decade. The most commonly studied class of TSAs are those …
Neoantigens: promising targets for cancer therapy
Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
SP Haen, MW Löffler, HG Rammensee… - Nature Reviews Clinical …, 2020 - nature.com
Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …
various malignancies. Such therapies promote the activation of antigen-specific T cells …
Cancer neoantigens and applications for immunotherapy
A Desrichard, A Snyder, TA Chan - Clinical Cancer Research, 2016 - AACR
Recent advances in immune checkpoint blockade therapy have revolutionized the treatment
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …
Chronic myeloid leukaemia
R Hehlmann, A Hochhaus, M Baccarani - The Lancet, 2007 - thelancet.com
Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …
the genotype led to a rationally designed therapy. As a result of its well known …
Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - nature.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
A Hochhaus, P La Rosée - Leukemia, 2004 - nature.com
Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …
Immunological off-target effects of imatinib
L Zitvogel, S Rusakiewicz, B Routy, M Ayyoub… - Nature Reviews …, 2016 - nature.com
Around 15 years ago, imatinib mesylate (Gleevec® or Glivec®, Novartis, Switzerland)
became the very first'targeted'anticancer drug to be clinically approved. This drug constitutes …
became the very first'targeted'anticancer drug to be clinically approved. This drug constitutes …
Chronic myeloid leukemia: diagnosis and treatment
A Quintás-Cardama, JE Cortes - Mayo Clinic Proceedings, 2006 - Elsevier
Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …
malignant disorders. Since the discovery of the presence of a unique and constant …
Gene fusion neoantigens: Emerging targets for cancer immunotherapy
Y Wang, T Shi, X Song, B Liu, J Wei - Cancer letters, 2021 - Elsevier
Tumor neoantigens play an important role in current cancer immunotherapies. The most
commonly studied class of tumor neoantigens contains those derived from single-nucleotide …
commonly studied class of tumor neoantigens contains those derived from single-nucleotide …